.Attribute Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a typical follow-up of 11 months, individuals with metastatic stomach tumors that received biomarker-matched therapies based on distributing growth DNA profiling presented a more significant professional advantage than those acquiring unrivaled treatment.